Press release
Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
February 6, 2023Business Services
THE NETHERLANDS and SOUTH KOREA, 6 February 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform …
Oxford University scientists’ AI diagnostic test accurately identifies known respiratory viruses in minutes
February 6, 2023Business Services
February 6th, 2023 – Oxford, United Kingdom – Nicolas Shiaelis and
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
February 6, 2023Business Services
Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and …
Businesses from the UK are in the top four foreign investors in Flanders in 2022
February 3, 2023Business Services
Investment figures released this week by Flanders Investment & Trade show that UK businesses are continuing to make significant investments …
IMFINZI (DURVALUMAB) IN COMBINATION WITH GEMCITABINE AND CISPLATIN APPROVED IN GREAT BRITAIN AS A FIRST-LINE TREATMENT FOR ADULT PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC BILIARY TRACT CANCER
February 3, 2023Business Services
London, UK, Thursday 2 February 2023 – AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has …
MHRA Approves RINVOQ®▼ (upadacitinib) as First Oral Advanced Therapy to Treat Adults with Moderately to Severely Active Crohn’s Disease
February 3, 2023Business Services
MAIDENHEAD, UK, 01 February 2023 – AbbVie (NYSE: ABBV) today announced that the UK Medicines and Healthcare products Regulatory Agency …
Phlo raises £10m to spearhead digital transformation in pharmacy sector
February 3, 2023Business Services
[Glasgow, Scotland] Phlo, UK digital pharmacy leaders, have closed a £10m Series A round led by family office Thairm Bio. …
PureTech to Present at the SVB Securities Global Biopharma Conference
February 1, 2023Business Services
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment …
Ellipses Pharma announces FDA approval of IND application for EP0042 for patients with acute myeloid leukaemia
February 1, 2023Business Services
Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …
ViCentra bolsters leadership team with the appointment of Leo Toole as Chief Financial Officer and expands European commercialization
February 1, 2023Business Services
February 1, Utrecht, The Netherlands ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most …
Sequana Medical announces grant of additional DSR® patent in United States
February 1, 2023Business Services
Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medic
Neuraxpharm announces closing of acquisition of established products from Sanofi
February 1, 2023Business Services
Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the …
Rare and Orphan disease expert Terebellum to launch incisive Specialty Pharmacy development bulletins, Specialty Pharmaceutical Pulse™
January 31, 2023Business Services
Global healthcare and business consulting services provider Terebellum is launching a brand-new monthly Specialty Pharmaceutical Pulse™ insights bulletin in the …
Vertex and CRISPR Therapeutics Announce MHRA Marketing Authorisation Application Validation for CRISPR/Cas9 GeneEdited Therapy, exagamglogene autotemcel (exa-cel
January 30, 2023Business Services
London, UK and ZUG, Switzerland, January 27, 2023 – Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics (NASDAQ: CRSP) today announced that …
BEXIMCO PHARMACEUTICALS LIMITED Half Year Results 2022-23
January 30, 2023Business Services
Beximco Pharmaceuticals Limited (“Beximco Pharma”, “BPL” or “the Company”; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
